A pilot study on effectiveness of oral mucositis pain control in hematopoietic stem cell transplant patients
Loading...
Date
2019-04
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Open Science Publishers LLP
Abstract
Effectiveness of oral mucositis (OM) pain control with the current standard of care management was assessed usingclinician and self-reported scales in hematopoietic stem cell transplant (HSCT) patients. A prospective observationalstudy was performed using clinician-assessed [World Health Organization (WHO)] Oral Toxicity Scales and selfreported scales [Oral Mucositis Daily Questionnaires (OMDQ)]. A total of 23 HSCT patients were included in thestudy. There were 100 recorded days of OM using WHO scores, and 144 recorded days of OM using OMDQ. A totalof 14/23 (60.9%) patients experienced mucositis. The presence of OM was significantly associated with increase inactual body weight [t(21) = 2.15, p = 0.044], body surface area (BSA) [t(21) = 2.31, p = 0.031] and body mass index(BMI) [t(21) = 2.13, p = 0.044], longer hospital stays [t(21) = 2.45, p = 0.023], and busulphan-based regimens (χ = 4.32,p = 0.038). The degree of pain relief was significantly inversely correlated to both the degree of WHO graded OMseverity (ρ = −0.586; p < 0.001) and the severity of self-reported pain (ρ = −0.375; p < 0.001). Both WHO and OMDQsignificantly positively correlated in the clinical setting (p < 0.001). In conclusion, this study highlights the potentialadvantages of using patient self-reported scales in the local clinical setting. The use of the OMDQ self-reported scalescould lead to earlier changes in therapy and may prove useful in HSCT patients.
Description
Keywords
Mucositis, stem cell transplant, WHO oral toxicity scale, OMDQ, pain.
Citation
Wong Shu Ping, Islahudin Farida. A pilot study on effectiveness of oral mucositis pain control in hematopoietic stem cell transplant patients. Journal of Applied Pharmaceutical Science. 2019 Apr; 2019 Apr: 027-032